M. Polée

2.2k citations

18 papers · 1.6k · 1 hit paper · h-index 13

Impact in

Oncology top 2%
- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
Surgery
- Esophageal Cancer Research and Treatment

Papers in

Oncology 11
- Pancreatic and Hepatic Oncology Research 6
- Colorectal Cancer Treatments and Studies 2
- Colorectal Cancer Surgical Treatments 2
- Bone health and treatments 1
Surgery 5
- Esophageal Cancer Research and Treatment 5

Co-authors: G. Stoter (5 shared papers)Peter Derk Siersema (5 shared papers)Ate van der Gaast (5 shared papers)Ted A.W. Splinter (3 shared papers)M.E.L. van der Burg (3 shared papers)Ferry A.L.M. Eskens (2 shared papers)T.C. Kok (2 shared papers)H.W. Tilanus (3 shared papers)
Journals: Annals of Oncology (3 papers)European Journal of Cancer (3 papers)BMC Cancer (2 papers)British Journal of Cancer (2 papers)Diabetic Medicine (1 paper)
Partner nations: Netherlands Norway

In The Last Decade

M. Polée

17 papers receiving 1.5k citations

M. Polée's Hit Papers

align trajectories log scale

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial 2020 · 1.1k citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2020 The Lancet Oncology

Peers

Countries citing papers authored by M. Polée

Since Specialization

Citations

This map shows the geographic impact of M. Polée's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Polée with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Polée more than expected).

Fields of papers citing papers by M. Polée

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Polée. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Polée. The network helps show where M. Polée may publish in the future.

Co-authors

The 25 scholars most cited alongside M. Polée, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with M. Polée Line = papers co-authored together M. Polée links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial The Lancet Oncology ·Renu R. Bahadoer, Esmée A. Dijkstra, Boudewijn van Etten, Corrie A.M. Marijnen, Hein Putter, Elma Meershoek‐Klein Kranenbarg, Annet G.H. Roodvoets, Irıs D. Nagtegaal Hit paper breakdown →	2020	1124
2	Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy British Journal of Cancer ·M. Polée, Wim C.J. Hop, T.C. Kok, Ferry A.L.M. Eskens, M.E.L. van der Burg, Ted A.W. Splinter, Peter Derk Siersema, Hugo W. Tilanus	2003	84
3	Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer British Journal of Cancer ·M. Polée, Ferry A.L.M. Eskens, M.E.L. van der Burg, Ted A.W. Splinter, Peter Derk Siersema, H.W. Tilanus, Jaap Verweij, G. Stoter	2002	62
4	Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group Annals of Oncology ·Johannes J.M. Kwakman, Lieke H. J. Simkens, Johan M. van Rooijen, Agnes J. van de Wouw, Albert J. ten Tije, G. J. M. Creemers, Mathijs P. Hendriks, Maartje Los	2017	59
5	Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial BMC Cancer ·Jacob L. van Dam, Eva M M Verkolf, Esther N. Dekker, Bert A. Bonsing, Svein Olav Bratlie, Lodewijk A.A. Brosens, Olivier R. Busch, Lydi M.J.W. van Driel	2023	41
6	A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study Annals of Oncology ·Anna K.L. Reyners, Linda de Munck, Frans Erdkamp, Willem M. Smit, Klaas Hoekman, Roy Iqbal Lalisang, H. de Graaf, A.N.M. Wymenga	2012	39
7	Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus Anti-Cancer Drugs ·M. Polée, T.C. Kok, Peter Derk Siersema, HW Tilanus, T. A. W. Splinter, G. Stoter, Ate van der Gaast	2001	35
8	Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro) European Journal of Cancer ·Hielke J. Meulenbeld, Erik D. van Werkhoven, J.L. Coenen, G. J. M. Creemers, Olaf J.L. Loosveld, Albert J. ten Tije, Sophie D. Fosså, M. Polée	2012	33
9	Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial Trials ·Marieke S. Walma, Steffi J. E. Rombouts, Lilly J. H. Brada, Inne H.M. Borel Rinkes, Koop P Bosscha, Rutger C. G. Bruijnen, Olivier R. Busch, G. J. M. Creemers	2021	17
10	Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer European Journal of Cancer ·M. Polée, Jaap Verweij, Peter Derk Siersema, H.W. Tilanus, Ted A.W. Splinter, G. Stoter, Ate van der Gaast	2002	16
11	Transanal total mesorectal excision and low anterior resection syndrome British journal of surgery ·J. Van Der Heijden, Seyed M. Qaderi, Rob H.A. Verhoeven, José A. E. Custers, Bastiaan R. Klarenbeek, Adriana J. G. Maaskant-Braat, Johannes de Wilt, Geerard L. Beets	2021	16
12	Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus Annals of Oncology ·M. Polée, H.W. Tilanus, F. A. L. M. Eskens, M.E.L. van der Burg, Peter Derk Siersema, G. Stoter, Ate van der Gaast +1 other	2003	14
13	The treatment and survival of elderly patients with locally advanced pancreatic cancer: A post-hoc analysis of a multicenter registry Pancreatology ·Lilly J. H. Brada, Marieke S. Walma, Ronald M. van Dam, Judith de Vos‐Geelen, Ignace H. J. T. de Hingh, G. J. M. Creemers, Mike S.L. Liem, Leonie J. Mekenkamp	2020	14
14	Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (the PELICAN trial): an international randomized controlled trial HPB ·Leonard W. F. Seelen, Lilly J. H. Brada, Marieke S. Walma, Steffi J. E. Rombouts, Rutger C. G. Bruijnen, Olivier R. Busch, Geert A. Cirkel, Ronald M. van Dam	2024	4
15	Catecholamines and Blood Glucose Control in Type 1 Diabetes Diabetic Medicine ·H. J. G. Bilo, Reinold O. B. Gans, M. Polée, Jan van der Maten, C. Popp‐Snijders, Ab J. M. Donker	1991	3
16	Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol BMC Cancer ·Thomas F. Stoop, Leonard W. F. Seelen, Freek R. van ‘t Land, A C Anouk Van der Hout, Jacobien C.M. Scheepens, Mahsoem Ali, Anne Margarethe Stiggelbout, B.M. van der Kolk	2025	2
17	Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group European Journal of Cancer ·Johannes J.M. Kwakman, Lieke H. J. Simkens, Johan M. van Rooijen, Agnes J. van de Wouw, Olaf J.L. Loosveld, G.J. Creemers, Mathijs P. Hendriks, Maartje Los	2017	1
18	Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer JAMA Network Open ·Leonard W. F. Seelen, Lilly J. H. Brada, Marieke S. Walma, Steffi J. E. Rombouts, Manon N.G.J.A. Braat, Thomas L. Bollen, Inne H.M. Borel Rinkes, Rutger C. G. Bruijnen	2026	0

About M. Polée

M. Polée is a scholar working on Oncology, Surgery, Reproductive Medicine, Endocrinology, Diabetes and Metabolism and Pulmonary and Respiratory Medicine, having authored 18 papers that have together received 1.6k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (6 papers), Esophageal Cancer Research and Treatment (5 papers), Colorectal Cancer Treatments and Studies (2 papers), Colorectal Cancer Surgical Treatments (2 papers), Bone health and treatments (1 paper), Ovarian cancer diagnosis and treatment (1 paper), Prostate Cancer Treatment and Research (1 paper) and Diabetes Management and Research (1 paper). The work is most often cited by research in Oncology (1.2k citations), Surgery (194 citations), Radiation (33 citations), Cancer Research (48 citations) and Geriatrics and Gerontology (12 citations). M. Polée has collaborated with scholars based in Netherlands and Norway. Frequent co-authors include G. Stoter, Peter Derk Siersema, Ate van der Gaast, Ted A.W. Splinter, M.E.L. van der Burg, Ferry A.L.M. Eskens, T.C. Kok, H.W. Tilanus, Jaap Verweij and Wim C.J. Hop. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, BMC Cancer, British Journal of Cancer and Diabetic Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

M. Polée

Impact in

Papers in i

In The Last Decade

M. Polée

M. Polée's Hit Papers

Peers

Countries citing papers authored by M. Polée

Fields of papers citing papers by M. Polée

All Works

About M. Polée

Explore authors with similar magnitude of impact

Papers in